For what's monitored at late third trimester appointments, see our 34 weeks pregnant guide. Prenatal care involves a scheduled sequence of appointments, scans, and blood tests — and for most first-time parents, the list of acronyms and unfamiliar terms can feel overwhelming. NIPT, NT scan, anomaly scan, GCT, GTT, GBS swab: what are they all, what do they actually look for, and what happens if a result is unexpected?
This guide gives you plain-language explanations of every standard prenatal test offered across most high-income healthcare systems. It covers what each test is, what it can and cannot tell you, and how to understand results. We also cover the two diagnostic tests (CVS and amniocentesis) that are only offered when screening tests identify increased risk.
This is the most important distinction in prenatal testing. A screening test assesses risk — it tells you the probability that a condition is present. A diagnostic test determines with certainty whether a condition is present. All non-invasive prenatal tests (blood tests, ultrasounds) are screening tests. Only invasive procedures (CVS, amniocentesis) are diagnostic.
This means: a high-risk result on a screening test does not mean your baby has a problem. It means your probability is higher than a threshold, and further investigation may be offered. Many pregnancies with high-risk screening results have entirely healthy babies.
Screening results are often expressed as a ratio, such as "1 in 200" or "1 in 4,500" for Down syndrome. This means that among pregnancies with these particular test results, 1 in 200 (or 1 in 4,500) would be affected. A result of 1 in 200 is considered higher-risk than 1 in 4,500 — but note that even a result of 1 in 200 still means 199 in 200 pregnancies at that risk level are unaffected. Understanding this framing helps avoid misinterpretation of what "high risk" actually means in everyday terms.
The booking blood tests are a panel of standard tests performed at your first antenatal appointment (typically weeks 8–12). They are not chromosomal screening; they assess your general health and identify conditions relevant to pregnancy management.
| Test | What it checks | Why it matters in pregnancy |
|---|---|---|
| Blood type and Rh factor | ABO blood group and Rhesus status | Rh-negative mothers need anti-D prophylaxis to prevent Rh sensitisation |
| Full blood count (FBC) | Haemoglobin, iron, platelets | Screens for anaemia and thrombocytopenia |
| Rubella immunity | Antibody levels from prior vaccination or infection | Rubella in first trimester causes serious fetal harm; non-immune mothers need postnatal vaccination |
| Hepatitis B surface antigen | Active hepatitis B infection | Neonates born to HBsAg-positive mothers need immediate vaccination and immunoglobulin |
| HIV | HIV antibodies | Treatment in pregnancy dramatically reduces mother-to-child transmission |
| Syphilis | VDRL/TPHA test | Congenital syphilis is preventable with antibiotic treatment in pregnancy |
| Thyroid stimulating hormone (TSH) | Thyroid function | Hypothyroidism in pregnancy increases risk of miscarriage and developmental issues if untreated |
Combined first trimester screening is offered between weeks 11 and 14, and consists of two components that are interpreted together to produce a single risk estimate:
These measurements are combined with the mother's age (which independently affects chromosomal risk) to produce a combined risk figure, most commonly expressed as a probability for Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13).
The detection rate of combined screening for Down syndrome is approximately 85–90%, with a false positive rate of around 5%. This means 1 in 20 women who screen positive will not have an affected baby. A high-risk result always requires further investigation before any decisions can be made.
Non-invasive prenatal testing (NIPT) — also called cell-free DNA (cfDNA) testing — analyses fragments of fetal DNA that circulate in the mother's blood from around 10 weeks of pregnancy. The fetal fraction of cfDNA is high enough for accurate analysis after 10 weeks in most pregnancies.
Despite its high accuracy, NIPT remains a screening test. A high-risk NIPT result must be confirmed by diagnostic testing (CVS or amniocentesis) before any definitive clinical or personal decisions are made. False positives can occur, particularly for rarer conditions, and are more common in low-risk populations. A positive NIPT result is also not a reason to consider termination before diagnostic confirmation.
NIPT is not universally funded by public health systems. In some countries (including Australia and the UK in many cases), it is available privately at cost, typically £300–600 or AUD$400–500. In the US, insurance coverage varies widely.
The anatomy scan — also called the anomaly scan, morphology scan, or 20-week scan — is performed between weeks 18 and 22 and is one of the most important appointments in pregnancy. It is a detailed ultrasound examination of fetal anatomy, checking for structural abnormalities that would not be detected by chromosomal screening.
The anatomy scan is thorough but not exhaustive. It cannot detect all conditions: minor heart defects, some brain abnormalities, small chromosome changes not visible on ultrasound, and conditions that develop after the scan (such as gestational diabetes complications) are not identified here. Finding a soft marker — an incidental finding associated with slightly increased risk but usually benign — can cause significant anxiety; your sonographer will explain the significance of any finding at the time.
Gestational diabetes mellitus (GDM) is a form of diabetes that develops during pregnancy, affecting approximately 7–10% of pregnancies. It usually causes no symptoms, which is why routine screening is important.
One-step (75g GTT): Fasting blood glucose, then 75g glucose drink, then blood at 1 hour and 2 hours. Used in Australia, most of Europe, and many other countries.
Two-step (50g GCT then 100g GTT if abnormal): Used in the US. A non-fasting glucose challenge test is done first; if above threshold, the 3-hour 100g glucose tolerance test follows.
If diagnosed with GDM, management typically involves blood sugar monitoring, dietary adjustment, and sometimes medication or insulin. Well-managed GDM carries low risk to mother and baby. GDM resolves after delivery in the vast majority of cases, though it increases the long-term risk of type 2 diabetes.
GBS is a bacterium carried in the vagina or rectum of approximately 20–25% of women without causing any symptoms. While harmless to the mother, GBS can be passed to the baby during labour and delivery and cause serious neonatal infection in a small proportion of cases.
A positive GBS swab means you carry the bacterium and will be offered intravenous antibiotics during labour to reduce transmission risk. It does not mean you are unwell or that your baby will be affected — antibiotic prophylaxis is highly effective at preventing neonatal GBS infection.
Growth scans assess fetal weight, abdominal circumference, and amniotic fluid volume using ultrasound. They are offered when there are concerns about fetal growth restriction (too small for dates), macrosomia (too large for dates), reduced fetal movements, or maternal conditions such as GDM or hypertension. They are not a routine part of pregnancy for uncomplicated low-risk pregnancies in most healthcare systems.
Rh-negative mothers who are carrying an Rh-positive baby risk developing antibodies against fetal blood cells — a process called Rh sensitisation — if fetal blood enters the maternal bloodstream. Anti-D immunoglobulin is given at specific points in pregnancy (typically at 28 weeks, and after any event that may cause feto-maternal haemorrhage) to prevent sensitisation. Without it, future pregnancies with Rh-positive babies can develop haemolytic disease of the newborn.
These two procedures are the only truly diagnostic tests in prenatal care. Unlike screening tests, they give a definitive chromosomal result — a yes or no answer about whether a specific chromosomal condition is present. They are offered when screening tests indicate increased risk, or in some cases when there is a family history of a specific genetic condition.
Receiving a high-risk or abnormal result from any prenatal test is one of the most anxiety-provoking experiences in pregnancy. It's important to understand both the clinical next steps and the emotional ones.
The waiting period between an abnormal screening result and a diagnostic result is often described as one of the most difficult experiences of pregnancy. Allow yourself to feel what you feel — anxiety, grief, denial, and hope can coexist. Reach out to your partner, trusted friends, or a counsellor rather than waiting until there is more information. Many fetal medicine units have specialist midwives or social workers available for support during this period.
No prenatal test is legally mandatory in most countries. All screening and diagnostic tests are offered, and you have the right to decline any of them. However, some tests — like the booking bloods and anatomy scan — are strongly recommended because they identify conditions that significantly affect management of your pregnancy. Discussing the purpose and implications of each test with your midwife or OB-GYN before deciding is always worthwhile.
NIPT is a screening test — it analyses cell-free fetal DNA in maternal blood to estimate the probability of chromosomal conditions. It is non-invasive, carries no risk to the pregnancy, but is not diagnostic: a high-risk NIPT result needs to be confirmed by amniocentesis or CVS. Amniocentesis is a diagnostic test — it directly analyses fetal chromosomes from amniotic fluid and gives a definitive yes/no answer, but carries a small risk of miscarriage (around 0.5–1% in experienced hands).
A high-risk result means your combined screening result (NT measurement + blood test markers) indicates a higher-than-average probability of a chromosomal condition. It does not mean your baby has a chromosomal condition. The threshold for "high risk" varies by country but is often around 1 in 150 or 1 in 300 for Down syndrome. A high-risk result triggers an offer of diagnostic testing (CVS or amniocentesis), not an automatic diagnosis. Many pregnancies with high-risk screening results have completely unaffected babies.
Yes — the anatomy scan is the same as the anomaly scan, the 20-week scan, or the mid-pregnancy scan. It is typically performed between weeks 18 and 22. It conducts a detailed survey of fetal anatomy, checking the brain, heart, spine, limbs, kidneys, and other organs. It can also check placental position and amniotic fluid volume.
A positive glucose screening test means your blood sugar was higher than expected after the glucose drink, and you will be offered a follow-up glucose tolerance test (GTT) for a definitive diagnosis. A positive GTT means gestational diabetes mellitus (GDM), which is manageable with dietary changes, blood sugar monitoring, and sometimes medication or insulin. GDM that is well-managed carries very low risk to mother and baby. It resolves in the vast majority of cases after birth, though it does increase long-term risk of type 2 diabetes.
BabyBloom helps you organise your antenatal appointments, log test results, and track your pregnancy week by week — so nothing falls through the cracks.
Track in the BabyBloom app — free